[go: up one dir, main page]

AR127255A1 - NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM - Google Patents

NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM

Info

Publication number
AR127255A1
AR127255A1 ARP220102690A ARP220102690A AR127255A1 AR 127255 A1 AR127255 A1 AR 127255A1 AR P220102690 A ARP220102690 A AR P220102690A AR P220102690 A ARP220102690 A AR P220102690A AR 127255 A1 AR127255 A1 AR 127255A1
Authority
AR
Argentina
Prior art keywords
compounds
hydrogen
c6alkyl
halogen
formula
Prior art date
Application number
ARP220102690A
Other languages
English (en)
Inventor
Bjoern Bartels
Giuseppe Cecere
Luca Gobbi
Maria Hernandez
- Humm Roland Clemencia
Morales Andres Miguel Olivares
Anglique Patiny-Adam
Valerie Runtz-Schmitt
Christian Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR127255A1 publication Critical patent/AR127255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos heterocíclicos novedosos que tienen la fórmula general (1) o (2), y sales farmacéuticamente aceptables de estos, en donde las variables son como se describen en la presente. Se proporcionan además composiciones farmacéuticas que incluyen los compuestos, procesos de elaboración de los compuestos y métodos de uso de los compuestos como medicamentos, en particular, métodos de uso de los compuestos para el tratamiento o prevención de trastornos neurológicos agudos, trastornos neurológicos crónicos y/o trastornos cognitivos. Reivindicación 1: Un compuesto de fórmula (1) o (2) o una sal farmacéuticamente aceptable de este, en donde: el resto de fórmula (3) se selecciona de: los compuestos del grupo de fórmulas (4); X se selecciona de C-R⁶ y nitrógeno; W es C o N; R¹ se selecciona de hidrógeno, alquil C₁-C₆, carbamoilo, alquil C₁-C₆-NHC(O)-, (alquil C₁-C₆)₂N-C(O)-, cicloalquil C₃-C₁₀-NH-C(O)- y heterocicloalquil-C(O)- de 3 - 14 miembros; en donde dicho heterocicloalquilo de 3 - 14 miembros está sustituido opcionalmente por 1 sustituyente seleccionado de halógeno y alcoxi C₁-C₆; R¹ᵃ se selecciona de hidrógeno y alquil C₁-C₆; o R¹ y R¹ᵃ, tomados en conjunto con los átomos de carbono a los que están unidos, forman un cicloalquenil C₃-C₁₀; R² se selecciona de hidrógeno y alquil C₁-C₆; R³ se selecciona de cloro y bromo; R⁴ se selecciona de alquil C₁-C₃, haloalquil C₁-C₂ y halógeno; R⁵ se selecciona de hidrógeno y halógeno; y R⁶ se selecciona de hidrógeno y halógeno.
ARP220102690A 2021-10-06 2022-10-05 NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM AR127255A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21201128 2021-10-06

Publications (1)

Publication Number Publication Date
AR127255A1 true AR127255A1 (es) 2024-01-03

Family

ID=78085501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102690A AR127255A1 (es) 2021-10-06 2022-10-05 NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM

Country Status (12)

Country Link
US (2) US12344614B2 (es)
EP (1) EP4426683A1 (es)
JP (1) JP2024536393A (es)
KR (1) KR20240073892A (es)
CN (1) CN118055923A (es)
AR (1) AR127255A1 (es)
AU (1) AU2022360084A1 (es)
CA (1) CA3232152A1 (es)
CO (1) CO2024003953A2 (es)
IL (1) IL311377A (es)
TW (1) TW202330477A (es)
WO (1) WO2023057415A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537773A (ja) 2021-09-29 2024-10-16 エフ． ホフマン－ラ ロシュ アーゲー ＧＡＢＡ Ａγ１ ＰＡＭとしての新規ベンゾジアゼピン誘導体
WO2023213757A1 (en) * 2022-05-03 2023-11-09 F. Hoffmann-La Roche Ag Pet tracers for visualizing gabaa gamma1 receptors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987052A (en) 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US3681343A (en) 1971-05-11 1972-08-01 Upjohn Co 6-phenyl-s-triazolo{8 4,3-a{9 {8 1,4{9 {0 benzodiazepines
US3734922A (en) 1971-05-11 1973-05-22 Upjohn Co Certain 4h-s-triazolo(4,3-a)(1,4)benzodiazepines
US4201712A (en) 1975-07-16 1980-05-06 Boehringer Ingelheim Gmbh Process for preparation of 6-aryl-4H-s-triazolo-[3,4-c]-thieno-[2,3-e]-1,4-diazepines
DE2533924C3 (de) 1975-07-30 1979-05-03 C.H. Boehringer Sohn, 6507 Ingelheim Verfahren zur Herstellung von 6- Aryl-4H-striazolo [3,4-c] thieno [2,3-e] 1,4-diazepinen
DE3435973A1 (de) 1984-10-01 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
DE3724031A1 (de) 1986-07-22 1988-01-28 Boehringer Ingelheim Kg Neue hetrazepine und verfahren zu ihrer herstellung
DE4101146A1 (de) 1991-01-16 1992-07-23 Boehringer Ingelheim Kg Neue in 6-position substituierte diazepine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2005525392A (ja) 2002-03-28 2005-08-25 ウィシス テクノロジー ファウンデーション，インコーポレイティド 減少された鎮静及び失調効果を有する抗不安薬剤
US9006233B2 (en) 2011-04-28 2015-04-14 Uwm Research Foundation, Inc. Gabaergic receptor subtype selective ligands and their uses
JP6715830B2 (ja) 2014-06-26 2020-07-01 ザ・ジョンズ・ホプキンス・ユニバーシティ 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター
US10259815B2 (en) * 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
CN109790170B (zh) 2016-08-16 2022-08-02 Uwm研究基金会有限公司 Gaba(a)受体调节剂和控制哮喘中气道高反应性和炎症的方法
WO2020198275A1 (en) 2019-03-25 2020-10-01 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
BR112022018828A2 (pt) 2020-03-31 2022-11-22 Hoffmann La Roche Derivados de benzodiazepina como gaba a gamma1 pams

Also Published As

Publication number Publication date
IL311377A (en) 2024-05-01
KR20240073892A (ko) 2024-05-27
CN118055923A (zh) 2024-05-17
CA3232152A1 (en) 2023-04-13
CO2024003953A2 (es) 2024-04-18
AU2022360084A1 (en) 2024-03-28
US20230142171A1 (en) 2023-05-11
WO2023057415A1 (en) 2023-04-13
JP2024536393A (ja) 2024-10-04
TW202330477A (zh) 2023-08-01
US12344614B2 (en) 2025-07-01
EP4426683A1 (en) 2024-09-11
US20250388586A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
PE20220140A1 (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
DOP2025000087A (es) Compuestos tricíclicos y sus usos
PE20241476A1 (es) Inhibidores de la ras
AR126351A1 (es) Compuestos y sus sales inhibidores del inflamasoma nlrp3
PE20240775A1 (es) Compuestos antivirales
AR127255A1 (es) NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM
AR125401A1 (es) Compuestos heterocíclicos novedosos
PE20232038A1 (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
PE20252677A1 (es) Amidas de azolipiridina piridazinona como inhibidores de sos1
CO2020001326A2 (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
CL2025001581A1 (es) Derivados de n-fenil-pirazolo[1,5-a]piridina-3-carboxamida como inhibidores de la c-kit quinasa de tipo salvaje para el tratamiento de la urticaria
AR123078A1 (es) Medicamentos antiplaquetarios y usos de estos
PE20240691A1 (es) Compuestos moduladores de gcn2 y usos de los mismos
PE20211769A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
AR121676A1 (es) DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1
PE20251689A1 (es) Moduladores de il-17a basados en diciclopropilo y usos de estos
AR123435A1 (es) Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr

Legal Events

Date Code Title Description
FA Abandonment or withdrawal